Uromodulin (Tamm-Horsfall protein) is the most abundant protein excreted in urine under physiological conditions. It is exclusively produced in the kidney and secreted into the urine via proteolytic cleavage. It has a protective role against urinary tract infections and renal stone formation. Mutations in the gene encoding uromodulin lead to rare autosomal dominant diseases, collectively referred to as uromodulin-associated kidney diseases. They are characterized by progressive tubulointerstitial damage, impaired urinary concentrating ability, hyperuricemia, renal cysts, and progressive renal failure. Recently, genome-wide association studies identified uromodulin as a risk factor for chronic kidney disease (CKD) and hypertension, and suggested that the level of uromodulin in urine could represent a useful biomarker for the development of CKD. Serum uromodulin determination exhibited superior characteristics required for a nephropathy marker that might be used for screening purposes. Using the cut-off 125.4 ng/ml it has a unique clinical sensitivity of 92.1% and specificity of 100.0%. BioVendor’s patent for the use of the serum uromodulin determination for the diagnosis of nephropathy is pending.

The Human Uromodulin ELISA kit is a sandwich ELISA intended for the quantitative determination of uromodulin in human urine, serum and plasma samples.

The Glucagon-like peptide-1 receptor (GLP-1R) was originally discovered from rat pancreatic islet cDNA. The GLP-1 receptor has also been cloned from human tissues including brain, lung, GI tract and heart. Hybridization studies have localized the human GLP-1R to 6p21. GLP-1 is an incretin hormone with antidiabetic action through its ability to stimulate insulin secretion, increase beta cell neogenesis, inhibit beta cell apoptosis, inhibit glucagon secretion, delay gastric emptying and induce satiety. It has therefore been explored as a novel treatment of type 2 diabetes. GLP-1 can improve contractility and glucose uptake in myocardiocytes and may protect against ischemic apoptosis in myocardial infarction. GLP-1 also has been found to improve endothelial function in patients with type 2 diabetes.

14% SDS-PAGE separation of Human GLP-1R
1. M.W. marker – 97, 66, 45, 31, 21, 14 kDa
2. reduced and boiled sample, 5μg/lane
3. non-reduced and non-boiled sample, 5μg/lane

BioVendor’s Uromodulin is a native protein purified from canine urine. The protein has been lyophilized from 0.5 mg/ml in deoinized water and does not contain any inert protein or antimicrobial agents.

12% SDS-PAGE separation of Canine Uromodulin Native protein
1.M.W. marker – 14, 21, 31, 45, 66, 97 kDa
2. reduced and heated sample, 5μg/lane – band was identified as Canine Uromodulin (LC-MS/MS)
3. non-reduced and non-heated sample, 5μg/lane

Omentin (Intelectin-1, Intestinal lactoferin receptor, Endothelial lectin HL-1, Galactofuranosebinding lectin) is newly identified secretory protein that is highly and selectively expressed in visceral adipose tissue but not subcutaneous adipose tissue (adipokine). Omentin-1 was shown to be the major circulating isoform in human plasma. Lean subjects had significantly higher omentin-1 plasma levels than obese and overweight subjects. Plasma omentin-1 levels were inversely correlated with BMI, waist circumference, leptin levels, and insulin resistance as measured by homeostasis model assessment and positively correlated with adiponectin and HDL levels. In summary, decreased omentin-1 levels are associated with increasing obesity and insulin resistance.

The antibodies have been obtained from rabbits or sheep, respectively, immunized with a recombinant human omentin protein produced in E.coli. The antibodies have been immunoaffinity purified using the immunization antigen.